$TOVX
Theriva Biologics, Inc. Stock $tovx

$tovx Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000114420418042887 Filed on August 08, 2018

Income Statement

Concept	2018 Q2	2017 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.430M	$1.640M
YoY Change	-12.8%	-23.72%
% of Gross Profit
Research & Development	$3.572M	$4.831M
YoY Change	-26.06%	-32.57%
% of Gross Profit
Depreciation & Amortization	$70.00K	$60.00K
YoY Change	16.67%	200.0%
% of Gross Profit
Operating Expenses	$5.003M	$6.475M
YoY Change	-22.73%	-30.46%
Operating Profit	-$5.003M	-$6.475M
YoY Change	-22.73%	-30.46%
Interest Expense	$10.00K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	$789.0K	$2.160M
YoY Change	-63.47%	-39.1%
Pretax Income	-$5.003M	-$6.475M
YoY Change	-22.73%	-30.46%
Income Tax
% Of Pretax Income
Net Earnings	-$4.214M	-$4.315M
YoY Change	-2.34%	-25.14%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.05	-$1.05
Diluted Earnings Per Share	-$1.05	-$1.05
COMMON SHARES
Basic Shares Outstanding	3.683M	3.514M
Diluted Shares Outstanding	3.683M	3.514M

Balance Sheet

Concept	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.130M	$13.38M
YoY Change	-46.71%	33.13%
Cash & Equivalents	$7.129M	$13.38M
Short-Term Investments
Other Short-Term Assets	$540.0K	$1.550M
YoY Change	-65.16%	-73.16%
Inventory
Prepaid Expenses	$130.0K	$382.0K
Receivables
Other Receivables	$0.00	$612.0K
Total Short-Term Assets	$7.664M	$14.92M
YoY Change	-48.63%	-5.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$731.0K	$800.0K
YoY Change	-8.63%	66.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$20.00K
YoY Change	0.0%	-33.33%
Total Long-Term Assets	$754.0K	$820.0K
YoY Change	-8.05%	60.78%
TOTAL ASSETS
Total Short-Term Assets	$7.664M	$14.92M
Total Long-Term Assets	$754.0K	$820.0K
Total Assets	$8.418M	$15.74M
YoY Change	-46.52%	-3.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.217M	$1.720M
YoY Change	-29.24%	-62.28%
Accrued Expenses	$1.000M	$2.960M
YoY Change	-66.22%	-1.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.319M	$12.33M
YoY Change	-64.97%	-18.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$350.0K	$450.0K
YoY Change	-22.22%	95.65%
Total Long-Term Liabilities	$350.0K	$450.0K
YoY Change	-22.22%	95.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.319M	$12.33M
Total Long-Term Liabilities	$350.0K	$450.0K
Total Liabilities	$4.672M	$10.91M
YoY Change	-57.18%	-29.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$200.8M
YoY Change
Common Stock	$194.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.487M	$4.830M
YoY Change
Total Liabilities & Shareholders Equity	$8.418M	$15.74M
YoY Change	-46.52%	-3.62%

Cashflow Statement

Concept	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$4.214M	-$4.315M
YoY Change	-2.34%	-25.14%
Depreciation, Depletion And Amortization	$70.00K	$60.00K
YoY Change	16.67%	200.0%
Cash From Operating Activities	-$4.310M	-$5.740M
YoY Change	-24.91%	-2.05%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	400.0K	5.640M
YoY Change	-92.91%	596.3%
NET CHANGE
Cash From Operating Activities	-4.310M	-5.740M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	400.0K	5.640M
Net Change In Cash	-3.910M	-100.0K
YoY Change	3810.0%	-98.02%
FREE CASH FLOW
Cash From Operating Activities	-$4.310M	-$5.740M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$4.310M	-$5.740M
YoY Change	-24.91%	-1.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent	395000	USD
CY2017Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent	590000	USD
CY2018Q2	us-gaap	Prepaid Insurance PrepaidInsurance	170000	USD
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	351000	USD
CY2018Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	130000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128918408	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128743616	shares
CY2018Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	98000	USD
CY2018Q2	syn	Prepaid Consulting Subscriptions And Other Expenses PrepaidConsultingSubscriptionsAndOtherExpenses	230000	USD
CY2017Q4	syn	Prepaid Consulting Subscriptions And Other Expenses PrepaidConsultingSubscriptionsAndOtherExpenses	290000	USD
CY2018Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	672000	USD
CY2017Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1283000	USD
CY2018Q2	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	625000	USD
CY2017Q4	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	658000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-4255000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7101000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	32029809	shares
CY2017Q4	syn	Warrant Liabilities WarrantLiabilities	4083000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3438000	USD
	us-gaap	Profit Loss ProfitLoss	-6540000	USD
	us-gaap	Profit Loss ProfitLoss	-7373000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	25000	shares
CY2018Q2	syn	Dilutive Shares Related To Warrants DilutiveSharesRelatedToWarrants	0	USD
	syn	Dilutive Shares Related To Warrants DilutiveSharesRelatedToWarrants	0	USD
CY2017Q2	syn	Dilutive Shares Related To Warrants DilutiveSharesRelatedToWarrants	0	USD
	syn	Dilutive Shares Related To Warrants DilutiveSharesRelatedToWarrants	0	USD
CY2018Q2	syn	Accrued Vendor Payments AccruedVendorPayments	221000	USD
CY2017Q4	syn	Accrued Vendor Payments AccruedVendorPayments	193000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	94000	USD
CY2018Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	295000	USD
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	201000	USD
CY2018Q2	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	143000	USD
CY2017Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	661000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4255000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7101000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6540000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4214000	USD
	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	0	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
CY2018Q2	syn	Subscriptions Receivable Current SubscriptionsReceivableCurrent	5000	USD
CY2017Q4	syn	Subscriptions Receivable Current SubscriptionsReceivableCurrent	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1233000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2006000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123005220	shares
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1526000	USD
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2018Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	32054809	shares
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	9000	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3438000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7249000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.50
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128918408	shares
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	120241593	shares
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1301000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1301000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1362000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2074000	USD
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3051000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3734000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1431000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1644000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3572000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4831000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6942000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10891000	USD
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	USD
CY2017Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	46000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	570000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	429000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1000000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128743616	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123005220	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	120241593	shares
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	731000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	872000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2018Q2	syn	Prepaid Clinical Research Organizations Expense Current PrepaidClinicalResearchOrganizationsExpenseCurrent	0	USD
CY2017Q4	syn	Prepaid Clinical Research Organizations Expense Current PrepaidClinicalResearchOrganizationsExpenseCurrent	46000	USD
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	130380517	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117254196	shares
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7129000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17116000	USD
	us-gaap	Operating Expenses OperatingExpenses	9993000	USD
	us-gaap	Operating Expenses OperatingExpenses	14625000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	5003000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	6475000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5003000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6475000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9993000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14625000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	535000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	827000	USD
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	130299305	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117172714	shares
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.52
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	141000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	116000	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Synthetic Biologics, Inc.
	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	0
CY2018Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.885	pure
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2017	syn	Deferred Tax Assetsfederal And Statutory Income Tax Rate DeferredTaxAssetsfederalAndStatutoryIncomeTaxRate	0.21	pure
CY2018Q2	us-gaap	Assets Current AssetsCurrent	7664000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	17943000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3438000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7249000	USD
CY2018Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-783000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2159000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
	dei	Entity Central Index Key EntityCentralIndexKey	0000894158
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-292000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-975000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-803000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-271000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.50
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	21600000	USD
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	15000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
CY2018Q2	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	23000	USD
CY2017Q4	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	23000	USD
CY2018Q2	us-gaap	Assets Assets	8418000	USD
CY2017Q4	us-gaap	Assets Assets	18838000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3453000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7252000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	789000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2160000	USD
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-526000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-877000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-711000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	896000	USD
	dei	Trading Symbol TradingSymbol	SYN
	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.02	pure
CY2018Q2	us-gaap	Profit Loss ProfitLoss	-4214000	USD
CY2017Q2	us-gaap	Profit Loss ProfitLoss	-4315000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-26000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-272000	USD
CY2018Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17000	USD
CY2017Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-60000	USD
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	132969743	shares
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-44000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	29000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10387000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11748000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-4197000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-4255000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6514000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7101000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1217000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2020000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	120000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2018Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	61000	USD
CY2017Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4258000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4255000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6634000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7101000	USD
CY2018Q2	syn	Warrant Liabilities WarrantLiabilities	645000	USD
CY2017Q4	syn	Warrant Liabilities WarrantLiabilities	4083000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y
CY2018Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1362000	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2074000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000	USD
CY2017	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6900000	USD
CY2017Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	73000	USD
CY2018Q1	us-gaap	Dividends Payable Current DividendsPayableCurrent	59000	USD
CY2018Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	61000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	128918408	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	123005220	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	128743616	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	120241593	shares
CY2018Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	95000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	90000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4319000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9793000	USD
	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	0	USD
	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	166000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	400000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5914000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	353000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	402000	USD
CY2017Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	9000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	4672000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	10195000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	400000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6080000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-9987000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-5679000	USD
CY2018Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	12173000	USD
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	12053000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19055000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13376000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	130000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	129000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	194186000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	192545000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-200803000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194170000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-6487000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-1496000	USD
CY2018Q2	us-gaap	Minority Interest MinorityInterest	-1940000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	-1914000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8427000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3410000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8418000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18838000	USD
CY2018Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1600000	USD

Files In Submission

Name	View Source	Status
0001144204-18-042887-index-headers.html	Edgar Link	pending
0001144204-18-042887-index.html	Edgar Link	pending
0001144204-18-042887.txt	Edgar Link	pending
0001144204-18-042887-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
syn-20180630.xml	Edgar Link	completed
syn-20180630.xsd	Edgar Link	pending
syn-20180630_cal.xml	Edgar Link	unprocessable
syn-20180630_def.xml	Edgar Link	unprocessable
syn-20180630_lab.xml	Edgar Link	unprocessable
syn-20180630_pre.xml	Edgar Link	unprocessable
tv499157_10q.htm	Edgar Link	pending
tv499157_ex31-1.htm	Edgar Link	pending
tv499157_ex32-1.htm	Edgar Link	pending
tv499157_img01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOVX
Theriva Biologics, Inc. Stock $tovx

2018 Q2 Form 10-Q Financial Statement

#000114420418042887 Filed on August 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX Theriva Biologics, Inc. Stock $tovx

2018 Q2 Form 10-Q Financial Statement

#000114420418042887 Filed on August 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX
Theriva Biologics, Inc. Stock $tovx